Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

While GLP-1 receptor agonists like semaglutide help with weight loss, new research shows users often fall short on vital nutrients, spotlighting the urgent need for tailored dietary guidance.

"The use of GLP-1 receptor ... before our study, it had not been examined on a truly national scale." Following semaglutide's approval for chronic weight management, a shift in the drug's ...

The outcomes highlight a revolutionary shift in obesity ... Substantial reduction in GLP-1 utilization and corresponding costs Responsible Prescribing prevents ongoing GLP-1 use by over 50% ...

While GLP-1 use may be temporary, the mindset shift is likely long-term. Consumers who start their weight loss journey with these medications are developing new habits and looking for products to ...

Its Phase 2b QUALITY trial evaluated the use of oral enobosarm in combination with semaglutide in a 168-patient randomized study ... default companion drug for quality GLP-1 fat loss.

Specific drug trends: The use of semaglutide and tirzepatide, potent GLP-1 receptor agonists, has seen a substantial rise in recent years. Patient population: The study utilized data from 217,442 ...

Weight Loss Drug Users Are Giving Up Their Vices This new study was prospective, meaning the researchers proactively tracked how people’s alcohol use changed after starting GLP-1 therapy (many ...

For this study, researchers analyzed U.S. federal research data in which people were asked about their GLP-1 prescriptions. Results showed that among people without diabetes, GLP-1 drug use rose ...

This makes semaglutide the first drug to show benefits in ... the growing amount of data regarding GLP-1 agonists in general and semaglutide specifically. Use has already been increasing and ...